NAUT Nautilus Biotechnology
- 2.865
- +0.025+0.88%
Nautilus Biotechnology News
Nautilus Biotechnology's ESG Challenge: Navigating the Rising Tide of Corporate Responsibility Standards
Nautilus Biotechnology Inc (NAUT) Q1 2024 Earnings Call Transcript Highlights: A Detailed ...
Earnings Call Summary | Nautilus Biotechnology(NAUT.US) Q1 2024 Earnings Conference
The following is a summary of the Nautilus Biotechnology, Inc. (NAUT) Q1 2024 Earnings Call Transcript:Financial Performance:Nautilus Biotechnology reported Q1 2024 total operating expenses of $21.6 m
Nautilus Biotechnology Shares Are Trading Higher After the Company Reported Better-than-expected Q1 EPS Results.
Nautilus Biotechnology Shares Are Trading Higher After the Company Reported Better-than-expected Q1 EPS Results.
Press Release: Nautilus Biotechnology Reports First Quarter 2024 Financial Results
Nautilus Biotechnology Reports First Quarter 2024 Financial Results SEATTLE, April 30, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or "Nautilus"), a company pioneering a sing
Nautilus Biotechnology 1Q Loss/Shr 15c >NAUT
Nautilus Biotechnology 1Q Loss/Shr 15c >NAUT
Nautilus Biotechnology Inc (NAUT) Q1 2024 Earnings: Narrower Loss Than Expected
Nautilus Biotechnology's Cash, Cash Equivalents, And Investments Were $247.7M As Of March 31, 2024
Nautilus Biotechnology's Cash, Cash Equivalents, And Investments Were $247.7M As Of March 31, 2024
Nautilus Biotechnology Q1 2024 GAAP EPS $(0.15) Beats $(0.17) Estimate
Nautilus Biotechnology (NASDAQ:NAUT) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.17) by 11.76 percent. This is a 25 percent decrease over losses of
Nautilus Biotechnology Reports First Quarter 2024 Financial Results
SEATTLE, April 30, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or "Nautilus"), a company pioneering a single molecule proteome analysis platform, today reported financial re
Nautilus Biotechnology to Announce First Quarter 2024 Financial Results on April 30, 2024
SEATTLE, April 11, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or "Nautilus"), a company pioneering a single molecule protein analysis platform, today announced it will repo
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersAvalo Therapeutics (NASDAQ:AVTX) stock rose 289.1% to $18.48 during Friday's pre-market session. The market value of their outstanding shares is at $14.8 million. Xilio Therapeutics (NASDAQ:XLO
Nautilus Biotechnology(NAUT.US) 10% Shareholder Buys US$41,477.85 in Common Stocks
$Nautilus Biotechnology(NAUT.US)$ 10% Shareholder Patel Sujal M purchased 14,474 shares of Common Stocks on Mar 8, 11, 2024 at an average price of $2.8657 for a total value of $41,477.85.Source: Annou
This Nautilus Biotechnology Insider Increased Their Holding In The Last Year
Sujal Patel Buys Handful Of Shares In Nautilus Biotechnology
Even if it's not a huge purchase, we think it was good to see that Sujal Patel, the Co-Founder of Nautilus Biotechnology, Inc. (NASDAQ:NAUT) recently shelled out US$99k to buy stock, at US$2.79 per sh
Nautilus Biotechnology(NAUT.US) 10% Shareholder Buys US$99,054.42 in Common Stocks
$Nautilus Biotechnology(NAUT.US)$ 10% Shareholder Patel Sujal M purchased 35,526 shares of Common Stocks on Mar 5, 6, 7, 2024 at an average price of $2.7882 for a total value of $99,054.42.Source: Ann
Earnings Call Summary | Nautilus Biotechnology(NAUT.US) Q4 2023 Earnings Conference
The following is a summary of the Nautilus Biotechnology, Inc. (NAUT) Q4 2023 Earnings Call Transcript:Financial Performance:Nautilus Biotechnology reported Q4 operating expenses of $20.0 million, lar
Nautilus Biotechnology Files $300M Mixed Securities Shelf
Nautilus Biotechnology 4Q Loss/Shr 14c >NAUT
Nautilus Biotechnology 4Q Loss/Shr 14c >NAUT
Nautilus Biotechnology Inc (NAUT) Reports Fiscal Year 2023 Financial Results
Analysis
Price Target
No Data
